Truist analyst Joon Lee says that while Alkermes (ALKS) announced the dual endpoints were met in the Vibrance-2 dose-ranging Phase 2 study ...
Clinical Trials Arena on MSN
Narcolepsy race heats up with Alkermes’ OX2R NT2 data but investors spooked
Alkermes is not the only company in late-stage development of an OXR2 candidate, with Centessa hot on its heels and Takeda ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback